Immuron Ltd: Immuron Plans Phase 2 Trial for IMM-529 following FDA review
Immuron Ltd: New US DoD Research Award to develop enhanced Travelan
Immuron Ltd: Immuron CEO to host webinar on MarketOpen Direct Connect
Immuron Ltd: Immuron Travelan record sales globally, Australia and USA
Immuron Ltd: Immuron CEO Steven Lydeamore to present at Sharewise
Immuron Ltd: IMM-529 pre-IND FDA filing
Immuron Ltd: Initial Director's Interest Notice JJ
Immuron Ltd: Final Director's Interest Notice RA
Immuron Ltd: Final Director's Interest Notice (SA)
Immuron Ltd: Immuron to host Live Virtual Event
Immuron Ltd: Immuron Travelan sales continued strong growth
Immuron Ltd: Change of Director's Interest Notice (DP)
Immuron Ltd: Travelan to progress to Phase 3 Clinical Trials in the US
Immuron Ltd: Trading Halt
Immuron Ltd: Immuron achieves record Travelan sales
Immuron Ltd: Immuron achieves record half yearly Travelan sales
Immuron Ltd: Immuron Clinical Trials Update
Immuron Ltd: First Patients Enrolled in Campylobacter Clinical Study
Immuron Ltd: Change of Director's Interest Notice (PB)
Immuron Ltd: Travelan Clinical Study Cohort 2 commences
No Data
No Data